>>Signaling Pathways>> Microbiology & Virology>> Parasite>>Fexinidazole (HOE 239)

Fexinidazole (HOE 239) (Synonyms: HOE239)

Catalog No.GC32094

펙시니다졸(HOE 239)(HOE 239)은 경구 활성, 강력한 니트로이미다졸 항트리파노솜 약물입니다.

Products are for research use only. Not for human use. We do not sell to patients.

Fexinidazole (HOE 239) Chemical Structure

Cas No.: 59729-37-2

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$35.00
재고 있음
5mg
US$32.00
재고 있음
10mg
US$32.00
재고 있음
50mg
US$44.00
재고 있음
100mg
US$61.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Fexinidazole is a 5-nitroimidazole drug currently in clinical development for the treatment of human sleeping sickness (human African trypanosomiasis [HAT]), caused by infection with species of the protozoan parasite Trypanosoma brucei. Target: Antiparasiticin vivo: Fexinidazole shows dose-related efficacy in the T. b. rhodesiense (STIB900) acute mouse model at intraperitoneal (i.p.) doses of 20 to 50 mg/kg/day and oral (per os [p.o.]) doses of 25 to 100 mg/kg/day given on four consecutive days, with 100 mg/kg/day p.o. being 100% curative. Fexinidazole is shown to be effective in the GVR35 mouse model, which mimics the advanced and fatal stage of the disease, when parasites have disseminated into the brain. [1]

[1]. Kaiser M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011 Dec;55(12):5602-8.

리뷰

Review for Fexinidazole (HOE 239)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Fexinidazole (HOE 239)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.